Angstrom Pharmaceuticals Announces Publication of the Discovery of the Cellular Target of Its A6 Phase II Clinical Compound Resulting From Its Joint Study With Apricus Biosciences

Published: Oct 26, 2011

SAN DIEGO, Oct. 26, 2011 (GLOBE NEWSWIRE) -- Angstrom Pharmaceuticals, Inc. ("Angstrom" or the "Company") announced today that the Molecular Cancer Therapeutic Journal, a peer reviewed journal, has published results elucidating the cellular target of its A6 phase II compound. The collaborative effort between Apricus Biosciences, Inc. (Nasdaq:APRI) ("Apricus Bio") and Angstrom resulted in the discovery of the mechanism of action by which Angstrom's A6 peptide blocks the migration of CD44-expressing cancer cells. Angstrom previously reported that results from a pharmacokinetic pre-clinical study showed significant improvement in the delivery and half life of A6, a proprietary peptide treatment for ovarian cancer that was in Phase II development by Angstrom. Specifically, the Company reported at that time that the incorporation of Apricus Bio's NexACT® technology enabled the dose of A6 to be cut by half, or from twice per day to once per day delivered subcutaneously, while achieving the same level of efficacy in the mouse lung metastasis model.

Back to news